InsidersTradesSigma
Follow the 우리바이오 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 우리바이오 has published 5 reports. Market capitalisation: €44bn. The latest transaction was disclosed on 30 June 2026 (Other). Among the most active insiders: 우리바이오. Every trade is openly available.
5
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
2 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,598 of 29,063 companies
40.3
score / 100
Value63
Quality18
FCF yld29%
Earn yld-22%
EV/EBITDA6.2x
ROE·
Gross mgn9.1%
Net mgn-0.9%
Debt/EBITDA4.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 June 2026
Acerca de 우리바이오
우리바이오 es una empresa de salud y farmacéutica que cotiza en el XKRX. Se centra en el desarrollo de soluciones biofarmacéuticas innovadoras.